Drug Profile
IDEA 073
Latest Information Update: 20 Jun 2008
Price :
$50
*
At a glance
- Originator IDEA
- Developer Celtic Pharma; IDEA
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Actinic keratosis; Skin disorders
Most Recent Events
- 23 Feb 2006 IDEA 073 has been licensed to Celtic Pharma worldwide
- 02 Jun 2005 No development reported - Phase-I for Actinic keratosis in Germany (unspecified route)
- 02 Jun 2005 Preclinical trials in Skin disorders in Germany (unspecified route)